Edition:
United Kingdom

Bristol-Myers Squibb Says Opdivo + Yervoy Now Approved In 3 Tumor Types


Wednesday, 11 Jul 2018 

July 11 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB’S OPDIVO® (NIVOLUMAB) + LOW-DOSE YERVOY® (IPILIMUMAB) IS THE FIRST IMMUNO-ONCOLOGY COMBINATION APPROVED FOR MSI-H/DMMR MCRC PATIENTS WHO PROGRESSED FOLLOWING TREATMENT WITH A FLUOROPYRIMIDINE, OXALIPLATIN AND....BRISTOL-MYERS SQUIBB CO - IN CHECKMATE -142 TRIAL, OPDIVO + YERVOY DEMONSTRATED AN OVERALL RESPONSE RATE OF 46%.BRISTOL-MYERS SQUIBB - OPDIVO + YERVOY IS NOW APPROVED IN THREE TUMOR TYPES, DOSING AND ADMINISTRATION VARIES BY TUMOR.BRISTOL-MYERS SQUIBB CO - OPDIVO + YERVOY IS ASSOCIATED WITH WARNINGS AND PRECAUTIONS SUCH AS IMMUNE-MEDIATED PNEUMONITIS, COLITIS, HEPATITIS.BRISTOL-MYERS SQUIBB - OPDIVO + YERVOY IS ALSO ASSOCIATED WITH WARNINGS & PRECAUTIONS LIKE ENDOCRINOPATHIES, NEPHRITIS & RENAL DYSFUNCTION, SKIN ADVERSE REACTIONS.BRISTOL-MYERS SQUIBB - OPDIVO + YERVOY IS ALSO ASSOCIATED WITH WARNINGS & PRECAUTIONS LIKE ENCEPHALITIS, OTHER ADVERSE REACTIONS; INFUSION REACTIONS.BRISTOL-MYERS SQUIBB CO - YERVOY CAN RESULT IN SEVERE AND FATAL IMMUNE-MEDIATED ADVERSE REACTIONS.